BRCA2 and prostate carcinoma: Given that BRCA2 is the largest single-gene subgroup and, at the time of trial design, had the best evidence for sensitivity to PARP inhibition in prostate cancer, it was considered important to balance the presence of BRCA2 across both treatment groups and so BRCA2 was included as a stratification factor.